NCT06624189

Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

Enrolling by Invitation
Not specifiedAges 18+Observational
NYU Langone Health
~1,300 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:Auto-pended bot liver ultrasound order

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound
Measured over Day 1
Hepatocellular Carcinoma
Cirrhosis
1 sites across 1 states
New York1
  • Saul Blecker · PRINCIPAL_INVESTIGATOR · NYU Langone Health

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

cirrhosis diagnosis,
6 months or more after since most recent imaging.

Exclusion

previous liver transplant,
HCC diagnosis,
receiving hospice care,
completed external imaging in the past 6 months.
  • Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver UltrasoundDay 1